Mr. Joshua Bartch reports

MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS

Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have resigned as directors of Mydecine Innovations Group Inc.

The departures are part of a larger organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency.

The company would like to express their gratitude to Mr. Michaels, Ms. Wu, Dr. Babaei and Dr. Hale for all of the valuable contributions they have made to the company and wish them the best of luck in all of their future endeavours. Mr. Michaels will continue to serve as chief operating officer for the organization. As a result of the resignations, the company is currently searching for candidates with a background in drug development to fill two board positions. Josh Bartch, Rob Roscow and Todd Heinzl have the best interest of the company's stockholders and will continue to serve on the board for the foreseeable future.

About Mydecine Innovations Group Inc.

Mydecine Innovations is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise.

We seek Safe Harbor.